BioWorld

Feb. 26, 2003

Dendreon Buying Corvas For $73M, Growing Cancer Program

Dendreon Corp. signed a definitive merger agreement to acquire Corvas International Inc. in a $72.9 million stock transaction that would combine the companies' cancer and cardiovascular pipelines and effectively double Dendreon's cash holdings. (BioWorld Today) Read More

Panel Explores Need To Navigate 'Unclear, Confusing' Payout Plans

Humidity Wakes Up Dead-To-World Anthrax Spores, Providing Keys To Practical Desktop Detection Kit

Ligand Signs Organon Unit As U.S. Marketing Partner For Avinza

Gene Logic Expanding Offerings With $52M TherImmune Acquisition

Genome Therapeutics Selling GenomeVision Unit To Agencourt

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...